ILLUMINA
19.2.2021 07:02:13 CET | Business Wire | Press release
February 19, 2021 -- Illumina, Inc. (Nasdaq: ILMN) today announced an agreement with the Institute of Medical Genetics and Applied Genomics at the University Hospital of Tübingen to assess the value of whole-genome sequencing (WGS) as a first-line diagnostic test for patients with genetic diseases and familial cancer syndromes. Illumina will support the new investigator-initiated study, called the Ge-Med Project, with sequencing, analysis and health economic expertise.
The Institute is the first laboratory in Germany accredited to perform clinical WGS. Previously, it used whole exome sequencing for the diagnosis of rare disease conditions which involves sequencing only around 1% of the genome known to contain the coding regions that provide instructions for making proteins.
The move to WGS is based on a two-year feasibility study by the Institute, supported by Illumina, which found that WGS provided improved diagnosis across a range of rare diseases. For example, as many as 75% of genetic eye diseases were accurately diagnosed using WGS, including some forms of disease that could only be identified by sequencing the entire genome. Similar results were found for rare childhood cancers and for conditions that cause developmental delay in children.
In addition to expanding the range of conditions for diagnosis, the new study will examine the ability of WGS to generate scores for the risk of common diseases based on genomic data. Known as a polygenic risk score, this will help identify individuals that may benefit from personalized healthcare management.
“We are delighted to be able to study whole genome sequencing as a diagnostic in an expanded range of conditions because we have demonstrated that it changes the management of patients who previously remained unresolved after whole exome and other sequencing approaches,” said Tobias Haack, Head of Molecular Diagnostics at the Institute of Medical Genetics and Applied Genomics, University Hospital of Tübingen.
“We are proud to support the University Hospital of Tübingen on this important step in their genomic work,” said Dr. Phil Febbo, Chief Medical Officer, Illumina. “Offering a clear diagnosis as well as disease risk for common conditions will give patients peace of mind and offer actionable steps to improve their overall health.”
Professor Olaf Rieß said, “We know that the exome isn’t the whole story when looking for answers to rare diseases and we have proven the value that WGS brings to families who otherwise would wait years for a diagnosis, or may never even receive one. Through the new study, we hope to help Germany lead the way in applying cutting edge genomics to improve healthcare.”
About Illumina
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit www.illumina.com and connect with us on Twitter , Facebook , LinkedIn , Instagram , and YouTube .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210218006118/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Agentic Crypto Payments Have Surged by 500%1 in the Last Three Months, Crypto Compliance Must Become Agentic Too10.9.2026 15:53:00 CEST | Press release
Elliptic is publishing eight principles for governing agentic on-chain risk: the Elliptic Standard Elliptic,the global leader in on-chain risk, today published the Elliptic Standard: eight principles for governing agentic on-chain risk. Elliptic has been at the intersection of financial crime and on-chain finance since 2013, long enough to recognize the shift to agentic transactions as a defining inflection point in financial crime risk, and to be the first to define what governing it demands. On-chain finance is now running at agentic speed. Machines are originating, authorizing and settling transactions at a volume no human team can review. Illicit actors are using AI to evade detection at a speed and volume that manual processes cannot track. Models built around human review were never designed for this world. They are already overwhelmed. Three forces are driving this shift. First, autonomous agents are increasingly the counterparty on both sides of a transaction, not just people i
Wasabi Establishes AI Business in Silicon Valley, Taps Pinaki Mukherjee to Lead as Senior Vice President & General Manager10.9.2026 15:00:00 CEST | Press release
Semiconductor and storage veteran to lead dedicated AI business to accelerate the independent storage foundation for AI labs, startups, and neocloud push as data demand grows to unprecedented scale Wasabi Technologies, the hot cloud storage company, today announced the formation of a dedicated AI business, and the appointment of semiconductor and storage veteran Pinaki Mukherjee as senior vice president and general manager to lead it. Wasabi stores hundreds of petabytes of AI data for frontier model labs, generative AI startups, and neocloud compute providers worldwide. This new AI business brings dedicated strategy, partnerships and go-to-market focus for this demand as AI infrastructure matures. “Mukherjee has a track record of driving the kind of high-value partnerships that move markets, and that’s exactly what this moment requires,” said Marty Falaro, president and COO of Wasabi. “AI workloads are pushing storage demand to a scale we've never seen, and Mukherjee is the right perso
Ant Group’s AI Health App AQ Reaches 150 Million Users as It Expands AI-powered Day-to-day Health Use Cases10.9.2026 14:47:00 CEST | Press release
At the 2026 INCLUSION · Conference on the Bund in Shanghai, Zhang Junjie, Vice President of Ant Group and Head of the Health Business, announced that Ant Group’s flagship AI health app AQ has reached 150 million users, handling nearly 20 million health inquiries per day. The new milestone also means AQ has grown its user base by 50% in just 8 months, since it announced 100 million users in February 2026, reflecting strong demand in China’s AI health space. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260910921103/en/ Ant Group’s AI health app AQ provides personalized health advice based on more than 10 health indicators. Health has become an increasingly important priority among Chinese consumers. According to Accenture’s China Consumer Insights report published in November 2025, the share of Chinese consumers who considered health a priority increased from 78% in 2021 to 87% in 2025, making it the top priority among the a
AULUMU Introduces A18 Series for iPhone 18 With Aramid Fibre, Hybrid Protection and Distinctive Finishes10.9.2026 14:43:00 CEST | Press release
Technology accessories brand aulumu has introduced the A18 Series for iPhone 18, a new collection of smartphone cases designed around lightweight protection, material innovation and distinctive visual finishes. The range includes the A18 Armor Shockproof Aramid Fiber Case, two ultra-slim aramid fibre models, the Ghost Lumen Transparent Case, and the Particle Vegan Leather Case. At the centre of the collection, the A18 Armor combines 1500D aramid fibre and thermoplastic polyurethane (TPU) in a one-piece construction. The hybrid structure pairs the light weight and woven texture of aramid fibre with the flexibility and cushioning properties of TPU. A full-wrap design covers the phone’s edges, while reinforced corners are intended to help distribute impact from everyday drops and bumps. The case is designed to provide drop protection from heights of up to 2 metres, with a 1.36 mm raised screen edge and a 1.3 mm raised camera frame providing additional protection around key areas. The A18
BGC Group Announces its First-Ever Fully AI Brokered Institutional Trade in Listed Equity Derivatives10.9.2026 14:30:00 CEST | Press release
Fully autonomous transaction between two institutional accounts marks milestone in AI-powered trading BGC Group Inc. (Nasdaq: BGC) (“BGC”), a leading global brokerage and financial technology company servicing financial markets, today announced it has launched Fenics AI, and that its subsidiary, Aurel BGC, has completed its first-ever fully AI brokered institutional trade in listed equity derivatives, using autonomous AI-powered systems to manage the trading workflow from price discovery through to execution. Fenics AI, BGC’s new proprietary AI trading technology, arranged this landmark transaction on September 3, 2026, in Eurex listed Swiss SMI options between two institutional accounts, including Hudson Bay Capital. This successful first AI trade follows rigorous development and testing to ensure compatibility with applicable market conventions, rules and governance. Fenics AI is expected to be made available to BGC’s clients during the fourth quarter 2026 to deliver significant effi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom